The Food and Drug Administration approved on Oct. 21 Relypsa’s Veltassa (patiromer) for oral suspension in the treatment of hyperkalemia.

In clinical trial, hyperkalemic patients saw a significant decrease in potassium levels while taking the new drug. The most common adverse reactions included constipation, hypomagnesemia, diarrhea and nausea. According to Relypsa, Veltassa will be available in January 2016 in the U.S.

Keywords: Constipation, Diarrhea, Hyperkalemia, Nausea, Potassium, Suspensions, United States Food and Drug Administration

< Back to Listings